First-in-Man intrathecal ppplication of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury
Background. Neutralization of central nervous system neurite growth inhibitory factors, for example, Nogo-A, is a promising approach to improving recovery following spinal cord injury (SCI). In animal SCI models, intrathecal delivery of anti-Nogo-A antibodies promoted regenerative neurite growth and...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 5, 2018
|
| In: |
Neurorehabilitation and neural repair
Year: 2018, Jahrgang: 32, Heft: 6-7, Pages: 578-589 |
| ISSN: | 1552-6844 |
| DOI: | 10.1177/1545968318776371 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1177/1545968318776371
|
| Verfasserangaben: | Klaus Kucher, Donald Johns, Doris Maier, Rainer Abel, Andreas Badke, Hagen Baron, Roland Thietje, Steven Casha, Renate Meindl, Baltazar Gomez-Mancilla, Christian Pfister, Rüdiger Rupp, Norbert Weidner, Anis Mir, Martin E. Schwab, Armin Curt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 168201195X | ||
| 003 | DE-627 | ||
| 005 | 20230428191327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191118s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1545968318776371 |2 doi | |
| 035 | |a (DE-627)168201195X | ||
| 035 | |a (DE-599)KXP168201195X | ||
| 035 | |a (OCoLC)1341251176 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kucher, Klaus |e VerfasserIn |0 (DE-588)1199833576 |0 (DE-627)1682011909 |4 aut | |
| 245 | 1 | 0 | |a First-in-Man intrathecal ppplication of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury |c Klaus Kucher, Donald Johns, Doris Maier, Rainer Abel, Andreas Badke, Hagen Baron, Roland Thietje, Steven Casha, Renate Meindl, Baltazar Gomez-Mancilla, Christian Pfister, Rüdiger Rupp, Norbert Weidner, Anis Mir, Martin E. Schwab, Armin Curt |
| 264 | 1 | |c June 5, 2018 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.11.2019 | ||
| 520 | |a Background. Neutralization of central nervous system neurite growth inhibitory factors, for example, Nogo-A, is a promising approach to improving recovery following spinal cord injury (SCI). In animal SCI models, intrathecal delivery of anti-Nogo-A antibodies promoted regenerative neurite growth and functional recovery. Objective. This first-in-man study assessed the feasibility, safety, tolerability, pharmacokinetics, and preliminary efficacy of the human anti-Nogo-A antibody ATI355 following intrathecal administration in patients with acute, complete traumatic paraplegia and tetraplegia. Methods. Patients (N = 52) started treatment 4 to 60 days postinjury. Four consecutive dose-escalation cohorts received 5 to 30 mg/2.5 mL/day continuous intrathecal ATI355 infusion over 24 hours to 28 days. Following pharmacokinetic evaluation, 2 further cohorts received a bolus regimen (6 intrathecal injections of 22.5 and 45 mg/3 mL, respectively, over 4 weeks). Results. ATI355 was well tolerated up to 1-year follow-up. All patients experienced ≥1 adverse events (AEs). The 581 reported AEs were mostly mild and to be expected following acute SCI. Fifteen patients reported 16 serious AEs, none related to ATI355; one bacterial meningitis case was considered related to intrathecal administration. ATI355 serum levels showed dose-dependency, and intersubject cerebrospinal fluid levels were highly variable after infusion and bolus injection. In 1 paraplegic patient, motor scores improved by 8 points. In tetraplegic patients, mean total motor scores increased, with 3/19 gaining >10 points, and 1/19 27 points at Week 48. Conversion from complete to incomplete SCI occurred in 7/19 patients with tetraplegia. Conclusions. ATI335 was well tolerated in humans; efficacy trials using intrathecal antibody administration may be considered in acute SCI. | ||
| 700 | 1 | |a Rupp, Rüdiger |d 1969- |e VerfasserIn |0 (DE-588)135739608 |0 (DE-627)570578388 |0 (DE-576)281757496 |4 aut | |
| 700 | 1 | |a Weidner, Norbert |e VerfasserIn |0 (DE-588)1035265907 |0 (DE-627)747116326 |0 (DE-576)176492577 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurorehabilitation and neural repair |d Thousand Oaks, Calif. : Sage, 1999 |g 32(2018), 6-7, Seite 578-589 |w (DE-627)362773661 |w (DE-600)2100545-X |w (DE-576)276557824 |x 1552-6844 |7 nnas |a First-in-Man intrathecal ppplication of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury |
| 773 | 1 | 8 | |g volume:32 |g year:2018 |g number:6-7 |g pages:578-589 |g extent:14 |a First-in-Man intrathecal ppplication of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury |
| 856 | 4 | 0 | |u https://doi.org/10.1177/1545968318776371 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191118 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1035265907 |a Weidner, Norbert |m 1035265907:Weidner, Norbert |d 910000 |d 911460 |e 910000PW1035265907 |e 911460PW1035265907 |k 0/910000/ |k 1/910000/911460/ |p 13 | ||
| 998 | |g 135739608 |a Rupp, Rüdiger |m 135739608:Rupp, Rüdiger |d 910000 |d 911460 |d 50000 |e 910000PR135739608 |e 911460PR135739608 |e 50000PR135739608 |k 0/910000/ |k 1/910000/911460/ |k 0/50000/ |p 12 | ||
| 999 | |a KXP-PPN168201195X |e 3541394544 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Klaus Kucher, Donald Johns, Doris Maier, Rainer Abel, Andreas Badke, Hagen Baron, Roland Thietje, Steven Casha, Renate Meindl, Baltazar Gomez-Mancilla, Christian Pfister, Rüdiger Rupp, Norbert Weidner, Anis Mir, Martin E. Schwab, Armin Curt"]},"recId":"168201195X","person":[{"family":"Kucher","role":"aut","display":"Kucher, Klaus","given":"Klaus"},{"display":"Rupp, Rüdiger","given":"Rüdiger","family":"Rupp","role":"aut"},{"family":"Weidner","role":"aut","given":"Norbert","display":"Weidner, Norbert"}],"note":["Gesehen am 18.11.2019"],"title":[{"title":"First-in-Man intrathecal ppplication of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury","title_sort":"First-in-Man intrathecal ppplication of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"14 S."}],"id":{"doi":["10.1177/1545968318776371"],"eki":["168201195X"]},"relHost":[{"language":["eng"],"part":{"text":"32(2018), 6-7, Seite 578-589","issue":"6-7","extent":"14","pages":"578-589","volume":"32","year":"2018"},"recId":"362773661","note":["Gesehen am 28.06.22"],"pubHistory":["13.1999 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"First-in-Man intrathecal ppplication of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injuryNeurorehabilitation and neural repair","title":[{"title_sort":"Neurorehabilitation and neural repair","title":"Neurorehabilitation and neural repair"}],"id":{"eki":["362773661"],"issn":["1552-6844"],"zdb":["2100545-X"]},"origin":[{"publisherPlace":"Thousand Oaks, Calif.","dateIssuedKey":"1999","dateIssuedDisp":"1999-","publisher":"Sage"}]}],"origin":[{"dateIssuedDisp":"June 5, 2018","dateIssuedKey":"2018"}]} | ||
| SRT | |a KUCHERKLAUFIRSTINMAN5201 | ||